What it is. A methyl donor: the molecule your cells use to tag DNA, build neurotransmitters, and patch membranes. You make it from methionine, and usually you make plenty 1. Supplementing is a bet that in certain slumps the supply runs short and adding more gets things moving.
Depression is the strongest case, and only as an add-on. In stalled patients who added SAM-e on top of an SSRI or SNRI, about a third improved versus a sixth on placebo, and a quarter reached remission versus a ninth 2. A later trial pointed the same way, weaker 3. As a stand-alone replacement, it flops: a Cochrane review saw no clear separation from placebo 4, and a monotherapy trial confirmed the null 5.
Joints are the second case. SAM-e matched ibuprofen, naproxen, and celecoxib on arthritic pain and function by month two, with a gentler gut 6. The honest catch: against placebo directly the pain gap was about four millimetres on a ten-centimetre scale, too small to feel 7. So it's as good as an anti-inflammatory pill, which is itself only modestly better than placebo, and much slower. Worth it mainly if your stomach can no longer tolerate the daily ibuprofen.
If you're going to try it, the dose is the whole game. Shelf-standard 200 mg and 400 mg tablets deliver a quarter of what worked in trials. The dose that did anything was 1200 to 1600 mg a day, split.
Weigh it against the standards first. For depression, SSRIs, therapy, aerobic exercise, and morning light all beat SAM-e as a first move; SAM-e's slot is the second one, after a partial response stalls 2. For joints, topical diclofenac gel gives most of the benefit with a fraction of the stomach risk, and exercise plus weight loss outperforms the pills over a year.
The fine print — when to skip it, and what people get wrong
Bipolar disorder: SAM-e can trigger mania like any antidepressant, so keep it clinician-supervised 9. Don't combine with MAO inhibitors, don't add it to your own SSRI without telling your prescriber, and know it may blunt levodopa for Parkinson's.
Most people who feel nothing under-dosed (one 400 mg tablet is a quarter of the working amount), took it with breakfast (food roughly halves absorption 8), or used it for ordinary low mood the trials never tested.
- 1Bottiglieri T (2002). S-Adenosyl-L-methionine (SAMe): from the bench to the bedside—molecular basis of a pleiotrophic molecule. American Journal of Clinical Nutrition. link
- 2Papakostas et al. (2010). S-adenosyl methionine (SAMe) augmentation of serotonin reuptake inhibitors for antidepressant nonresponders with major depressive disorder: a double-blind, randomized clinical trial. American Journal of Psychiatry. link
- 3Sarris et al. (2018). Adjunctive S-adenosylmethionine (SAMe) in treating non-remittent major depressive disorder: an 8-week double-blind, randomized, controlled trial. European Neuropsychopharmacology. link
- 4Galizia et al. (2016). S-adenosyl methionine (SAMe) for depression in adults. Cochrane Database of Systematic Reviews. link
- 5Sarris et al. (2020). S-Adenosylmethionine (SAMe) monotherapy for depression: an 8-week double-blind, randomised, controlled trial. Psychopharmacology. link
- 6Najm et al. (2004). S-adenosyl methionine (SAMe) versus celecoxib for the treatment of osteoarthritis symptoms: a double-blind cross-over trial. BMC Musculoskeletal Disorders. link
- 7Rutjes et al. (2009). S-Adenosylmethionine for osteoarthritis of the knee or hip. Cochrane Database of Systematic Reviews. link
- 8Aliani et al. (2020). Pharmacokinetic study of a novel oral formulation of S-adenosylmethionine (MSI-195) in healthy subjects: dose escalation, food effect and comparison to a commercial nutritional supplement product. BMC Pharmacology and Toxicology. link
- 9Mischoulon D, Fava M (2002). Role of S-adenosyl-L-methionine in the treatment of depression: a review of the evidence. American Journal of Clinical Nutrition. link
SAM-e (S-Adenosylmethionine)
Daily pill, divided dose, on an empty stomach to preserve bioavailability (AUC drops to ~55% with food per Aliani 2020). No injections, no monitoring required at standard use. Trivial behavioral burden once routine.
Therapeutic doses are 1200–1600 mg/day; OTC pricing on enteric-coated 400 mg tablets runs $0.10–0.20/tablet, so $150–300/year at depression or OA dose. Sits in the minor-cost band, higher than most generic supplements but well below brand-name prescription antidepressants without insurance.
Two replicated placebo-controlled adjunctive trials show response rates roughly double placebo when added to SSRIs/SNRIs in non-responders (Papakostas 36.1% vs 17.6%; Sarris directionally similar). Monotherapy effect is weaker — the 2016 Cochrane review found no significant separation, but the older Bressa meta-analysis (mostly parenteral) reported effect size −0.65 vs placebo, and the 2024 Cuomo meta-analysis estimated −0.58. Meaningful but not dominant — a clear named effect.
Najm 2004 (n=61 cross-over) showed SAMe 1200 mg/day reached celecoxib-equivalent pain relief in knee OA by month two; Soeken 2002 meta-analysis pooled NSAID-comparison trials at parity. The 2009 Rutjes Cochrane review found a clinically trivial placebo-controlled effect (~0.4 cm on 10 cm VAS) — so the headline is honest as 'real but small, slow onset.' Pruritus relief in cholestatic liver disease adds a second short-term symptomatic effect (Frezza 1990).
Multiple RCTs across three indications, but the contemporary high-quality reviews are unfriendly: 2016 Cochrane (depression, Galizia) graded evidence low to very low; 2009 Cochrane (OA, Rutjes) found placebo-controlled effect non-significant. Two positive adjunctive depression RCTs (Papakostas 2010, Sarris 2018) and a recent positive meta-analysis (Cuomo 2024) keep the case alive but not strong. The reference enteric-coated formulation's bioavailability is genuinely poor (Aliani 2020), which weighs against translating older parenteral-trial effects to modern oral practice.